Skip to main content

PerkinElmer, Cerep Partner on Drug Discovery Tools

NEW YORK (GenomeWeb News) – PerkinElmer today announced that it has signed a co-marketing agreement with Cerep to provide custom drug discovery tools and services to customers.
 
Under the agreement, PerkinElmer will exclusively market Cerep’s target screening and profiling services to its customers. The firms also will jointly promote PerkinElmer’s assay technologies and Cerep’s high-throughput screening and profiling services to the drug discovery market.
 
PerkinElmer said that the alliance provides its customers with an option to work with a single vendor throughout the entire drug discovery process.
 
“This agreement represents the latest step in our strategy to build the most comprehensive offering in biochemical and cellular screening for drug discovery,” PerkinElmer President and CEO Robert Friel said in a statement.
 
The firm rapidly expanded its cellular analysis and screening business early in 2007 with the acquisitions of Evotec Technologies, Euroscreen Products, and Improvision.
 
Paris-based Cerep specializes in custom binding, cellular, and tissue assay services. It also has developed the BioPrint pharmacoinformatics platform.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.